A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Public ClinicalTrials.gov record NCT06365853. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) expression.
Study identification
- NCT ID
- NCT06365853
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 108 participants
Conditions and interventions
Interventions
- Mirvetuximab Soravtansine Drug
- Lubricating Eye Drops Drug
- Prednisolone acetate ophthalmic suspension 1% eye drops Drug
- Brimonidine tartrate ophthalmic solution eye drops Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 29, 2024 (Actual)
- Primary completion
- Feb 2027 (Estimated)
- Completion
- Feb 2027 (Estimated)
- Last update posted
- Aug 21, 2026
2024 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles /ID# 269339 | Los Angeles | California | 90095 | — |
| UCSF Medical Center /ID# 280425 | San Francisco | California | 94158-2531 | — |
| Norton Cancer Institute - St. Matthews /ID# 269070 | Louisville | Kentucky | 40207 | — |
| Holy Cross Hospital - Silver Spring /ID# 269344 | Silver Spring | Maryland | 20910 | — |
| Mercy David C. Pratt Cancer Center /ID# 269350 | St Louis | Missouri | 63141 | — |
| The Center Of Hope /ID# 269348 | Reno | Nevada | 89511 | — |
| Holy Name Medical Center /ID# 269340 | Teaneck | New Jersey | 07666 | — |
| New York Oncology Hematology - Albany Cancer Center /ID# 269345 | Albany | New York | 12206-5013 | — |
| Women'S Cancer Care Associates /ID# 269980 | Albany | New York | 12208 | — |
| Duke Cancer Institute /ID# 269342 | Durham | North Carolina | 27710 | — |
| Summa Health /ID# 269349 | Akron | Ohio | 44304-1407 | — |
| University of Texas - Southwestern Medical Center /ID# 269341 | Dallas | Texas | 75235 | — |
| Memorial Hermann Southeast Hospital /ID# 269347 | Houston | Texas | 77089 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06365853, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06365853 live on ClinicalTrials.gov.